Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN

Blood (2024) 144 (22): 2336–2348.

https://doi.org/10.1182/blood.2024024373

Published: 2024

Includes: Supplemental data

Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Blood (2024) 144 (Supplement 1): 868.

https://doi.org/10.1182/blood-2024-193681

Published: 2024

Journal Articles

Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Jingtao Huang, Jing Zhou, Shixuan Zhang, Ruoxuan Zhang, Zengkai Pan, Luxiang Wang, Chuanhe Jiang, Jiayu Huang, Zilu Zhang, Yanmin Zhao, Yang Cao, Jianmin Wang, Xiaoxia Hu

Blood (2024) 144 (Supplement 1): 268.

https://doi.org/10.1182/blood-2024-202762

Published: 2024

Journal Articles

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 341.

https://doi.org/10.1182/blood-2024-193589

Published: 2024

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Jing-Zhou Hou, Rushir Choksi, Gregory A. Maglinte, Anupama Vasudevan, Anna Rui, Brandon Wang, Hoa Pham, Ann Lasn, Simon Blanc

Blood (2024) 144 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2024-207760

Published: 2024

Journal Articles

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Jing-Zhou Hou, Rushir Choksi, Anupama Vasudevan, Anna Rui, Poras Davé, Mike Gart, Brandon Wang, Prateesh Varughese, Simon Blanc

Blood (2024) 144 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2024-199765

Published: 2024

Journal Articles

Purine Metabolism Modulates Leukemia Stem Cell Maintenance in MLL-Rearranged Acute Leukemia

Xiangguo Shi, Minhua Li, Lin Tan, Zian Liu, Yudan Zhu, Tiessen Jonathan, Jing Zhou, Mengdie Feng, Yuki Kageyama, Hassan Samee, Kristen Andreozzi, Philip Lorenzi, Koichi Takahashi, Michalis Agathocleous, Daisuke Nakada

Blood (2023) 142 (Supplement 1): 582.

https://doi.org/10.1182/blood-2023-190833

Published: 2023

Journal Articles

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Jing-Zhou Hou, Simon Blanc, Gregory A Maglinte, Anupama Vasudevan, Anna Rui, Michael Gart, Hoa Pham, Lindsay Aton, Brandon Wang, Rushir Choksi

Blood (2023) 142 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2023-174915

Published: 2023

Journal Articles

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Jing-Zhou Hou, Michael Gart, Anupama Vasudevan, Harvey I. Katzen, Rushir Choksi, Simon Blanc

Blood (2023) 142 (Supplement 1): 130.

https://doi.org/10.1182/blood-2023-178685

Published: 2023

Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2023-182045

Published: 2023

Journal Articles

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Jessica Lynn Root, Poonam N Desai, Patrick K Reville, Christopher Ly, Bofei Wang, Fatima Z Jelloul, Jing Zhou, Sean Gregory Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2023-188268

Published: 2023

Journal Articles

Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

Sameh Gaballa, Ranjit Nair, Ryan W Jacobs, Sumana Devata, Seok-Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing-Zhou Hou

Blood (2023) 142 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2023-174668

Published: 2023

Journal Articles

UBC9 Deficiency Accelerates AML Progression By Downregulating PARP1 Sumoylation and Subsequently Activating the NF-ΚB Pathway

Jing Zhou, Xing Chen, Yang Cao, Liang Huang, Gaoxiang Wang

Blood (2023) 142 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2023-185601

Published: 2023

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, Vinod A. Pullarkat

Blood (2022) 140 (Supplement 1): 8993–8995.

https://doi.org/10.1182/blood-2022-158500

Published: 2022

Journal Articles

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Jing-Zhou Hou, Ryan Jacobs, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don A. Stevens, Jin Seok Kim, Ben Buelow, Ranjit Nair

Blood (2022) 140 (Supplement 1): 1474–1475.

https://doi.org/10.1182/blood-2022-166385

Published: 2022

Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis

Blood (2022) 140 (Supplement 1): 6145–6146.

https://doi.org/10.1182/blood-2022-156468

Published: 2022

Journal Articles

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)

Edimara Reis, Rebecca Buonpane, Hamza Celik, Caroline Marty, Angela Lei, Fatoumata Jobe, Mark Rupar, Yue Zhang, Darlise DiMatteo, Rahel Awdew, William Vainchenker, Jing Zhou, Ian Hitchcock, Isabelle Plo, Horacio Nastri, Patrick Mayes

Blood (2022) 140 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2022-159435

Published: 2022

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

https://doi.org/10.1182/blood-2021-150371

Published: 2021

NARROW

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

Purine Metabolism Modulates Leukemia Stem Cell Maintenance in MLL-Rearranged Acute Leukemia

Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices

Assessing Adoption of Standard of Care and Comparing Clinical and Demographic Differences in First-Line (1L) Treatment (Tx) of Chronic Lymphocytic Leukemia (CLL)

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

UBC9 Deficiency Accelerates AML Progression By Downregulating PARP1 Sumoylation and Subsequently Activating the NF-ΚB Pathway

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only